Brightsurf Science News and Current Science News Events
 

Multiple Myeloma News | Multiple Myeloma Current Events
Page 1 of 12 | 285 Results
Previous0102030405060708091011   Next   
Sort By: Page Views | Date
Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma
Mayo Clinic Cancer Center researchers have found that chaetocin, a by-product of a common wood mold, has promise as a new anti-myeloma agent.   view more (2007-04-16)

Keeping cancer at bay: Long-term therapy in the fight against multiple myeloma
There is no known cure for multiple myeloma, so its diagnosis means high-dose chemotherapy followed by repeated treatments with each relapse of the cancer - a watch and wait approach.   view more (2006-11-06)

Obesity found to be a risk factor for multiple myeloma
An obese person is more likely than a lean person to develop multiple myeloma, according to researchers from Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health.   view more (2007-07-20)

An advanced genetic diagnostic method for multiple myeloma
A researcher at the University of Navarra, Borja Sáez Ochoa, has proposed a new genetic diagnostic method for multiple myeloma (MM), a type of bone marrow cancer, which permits the detection of this disease in earlier stages.   view more (2006-09-12)

Oral Drug Sets a New Survival Standard for Bone Marrow Cancer
Findings from two large, international clinical trials show "unprecedented" survival for patients with multiple myeloma, a blood cancer that occurs in the blood-making cells of bone marrow.   view more (2007-11-26)

Stem cells make bone marrow cancer resistant to treatment
Scientists at the Johns Hopkins Kimmel Cancer Center say they have evidence that cancer stem cells for multiple myeloma share many properties with normal stem cells and have multiple ways of resisting chemotherapy and other treatments.   view more (2008-01-14)

3-drug combination 'extremely promising' as first-line therapy for multiple myeloma
A new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology.   view more (2007-12-12)

Emory researchers identify signaling protein for multiple myeloma
Researchers at Emory University's Winship Cancer Institute are the first to discover a mechanism that plays a critical role in the multiple myeloma cell cycle and survival.   view more (2007-09-11)

Drug combination slows progression of treatment resistant bone marrow cancer
Combining a newly formulated drug with one that is already a standard treatment slows the progression of multiple myeloma, an advanced cancer of the bone marrow cells.   view more (2006-12-13)

Mayo Clinic research shows promise for myeloma patients
Mayo Clinic Cancer Center investigators report that combination therapy with lenalidomide (RevlimidTM) and dexamethasone (combination is called Rev/Dex) looks like a breakthrough treatment for multiple myeloma.   view more (2005-09-02)

Gene profiling can single out the worst cases of multiple myeloma and guide therapy
Multiple myeloma patients vary widely in how they respond to treatment, but now researchers at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences have identified a small subset of genes whose activity could predict high-risk cases and potentially guide... view more (2007-09-19)

Thalidomide treatment proves better than conventional chemotherapy for multiple myeloma
When people hear "thalidomide," many think "birth defects," however, evidence has come to light that this once-banned drug can be used as a potent anti-cancer treatment. In a new study, researchers from the University of Bologna, Italy, demonstrate that Thal-Dex (thalidomide... view more (2005-06-21)

Studies at cancer conference show new therapies changing outlook for blood cancer patients
The International Myeloma Foundation (IMF) - conducting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today noted that multiple studies presented at the 2006 Annual Meeting of the American Society of Hematology (ASH) illustrate... view more (2006-12-11)

Multiple myeloma clinical trial closes early
Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone.   view more (2007-04-05)

Mayo Clinic Cancer Center — individualizing treatment for multiple myeloma patients
Researchers at Mayo Clinic Cancer Center, in cooperation with industry partners, have, for the first time, identified tumor specific alterations in the cellular pathway by which the multiple myeloma drug bortezomib (Velcade) works, and they have identified nine new genetic mutations in cancer cells... view more (2006-12-11)

Genome changes tracked during multiple myeloma initiation, progression and treatment
Scientists have made significant progress toward elucidating key genetic events associated with the development and progression of multiple myeloma (MM), an incurable malignancy that is the second most common cancer of the blood.   view more (2006-04-11)

A chemotherapy drug packs a one-two punch
Cancer can be wily, and those who treat the disease have amassed a wide array of weapons with which to fight it and kill tumors.   view more (2007-02-21)

Investigating the measles virus as a tool to kill multiple myeloma
Mayo Clinic Cancer Center has opened a new Phase I clinical trial testing an engineered measles virus against multiple myeloma, a cancer of the bone marrow that currently has no cure. This is the third of a series of molecular medicine studies in patients testing the potential of measles to kill... view more (2007-03-06)

ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
Results from two investigational Phase I trials of ZOLINZA® (vorinostat) in combination with bortezomib provide preliminary anti-tumor activity in patients with relapsed and/or refractory multiple myeloma.   view more (2007-12-10)

Scientists discover new genetic subtypes of common blood cancer
Scientists at Dana-Farber Cancer Institute and collaborators have identified four distinct genetic subtypes of multiple myeloma, a deadly blood cancer, that have different prognoses and might be treated most effectively with drugs specifically targeted to those subtypes.   view more (2006-04-11)

Penn's Abramson Cancer Center part of major phase III study for myeloma
Researchers from the Abramson Cancer Center of the University of Pennsylvania announced today that findings from two large, international clinical trials show unprecedented survival for patients with multiple myeloma, a cancer that occurs in the blood-making cells of bone marrow.   view more (2007-11-26)

Looking through the eyes of a mouse, scientists monitor circulating cells in its bloodstream
A team of researchers from the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH) and Harvard Medical School (HMS) have developed an optical device that allows them to peer through the eyes of a mouse and monitor the cells passing through its bloodstream.   view more (2007-12-04)

Trial at Jefferson shows new drug may help cancer patients who need stem cell transplants
A new drug may help cancer patients mobilize the cells necessary to restore their blood-forming system after high-dose chemotherapy, according to results from a clinical trial at the Kimmel Cancer Center at Thomas Jefferson University Hospital in Philadelphia and at other centers across the nation.   view more (2005-09-09)

REVLIMID improves overall survival and delays disease progression in multiple myeloma patients
Celgene Corporation (NASDAQ: CELG) announced updated clinical data from two Phase III pivotal studies evaluating REVLIMID (lenalidomide) plus dexamethasone in previously treated multiple myeloma patients.   view more (2005-12-13)

Novel drug preventing protein recycling shows potential for treating leukemia
Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found that a novel targeted therapy effectively treats acute leukemia in animal models by preventing cancer cells from being purged of damaged proteins.   view more (2007-04-20)
Page 1 of 12 | 285 Results
Previous0102030405060708091011   Next   
Sort By: Page Views | Date
© 2008 BrightSurf.com